logo
Twitter
Discord
Email
logo
logo
Enliven Therapeutics, Inc.NASDAQ - ELVN
Reports
Search reports
Name
Reporting Date
Filing Date
2024-09-30 10-Q2024-09-302024-11-13
2024-06-30 10-Q2024-06-302024-08-13
2024-03-31 10-Q2024-03-312024-05-14
2023-12-31 10-K2023-12-312024-03-14
2023-09-30 10-Q2023-09-302023-11-09
2023-06-30 10-Q2023-06-302023-08-10
2023-03-31 10-Q2023-03-312023-05-11
2022-12-31 10-K2022-12-312023-02-10
2022-09-30 10-Q2022-09-302022-10-25
2022-06-30 10-Q2022-06-302022-08-03
2022-03-31 10-Q2022-03-312022-05-06
2021-12-31 10-K2021-12-312022-03-15
2021-09-30 10-Q2021-09-302021-11-09
2021-06-30 10-Q2021-06-302021-08-06
2021-03-31 10-Q2021-03-312021-05-11
2020-12-31 10-K2020-12-312021-03-05
2020-09-30 10-Q2020-09-302020-11-05
2020-06-30 10-Q2020-06-302020-08-14
2020-03-31 10-Q2020-03-312020-05-07
1
20 / page
About
Name
Enliven Therapeutics, Inc.
Overview
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
Show More
CEO
Mr. Samuel S. Kintz M.B.A.
Industry
Biotechnology
Exchange
NASDAQ
Listing Date
2020-03-12
Address
6200 Lookout Road, Boulder, CO, 80301, United States
Tel
720-647-8519
Website
https://www.enliventherapeutics.com